In humans with AD, the PEGASUS phase 2a clinical trial compared a treatment combining the HDAC inhibitor sodium phenylbutyrate and the hydrophilic bile acid taurursodiol to a placebo over 24 weeks, focusing on the mechanistic targets and pathways. This evidence concerns the gene HDAC9 and Alzheimer disease.